RxDoctor Payments Data

Anand Vaidya, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1528119591

Payments from drug & device makers

$27,939in general payments, 2019–2025

Across 21 payments — averaging $1330.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$9K
  • Astrazeneca UK Limited$8K
  • HRA Pharma RARE Diseases$5K
  • AstraZeneca$4K
  • Vertex$877
  • Modernatx, Inc.$450

What the payments were for

  • Consulting fees$27,62999%
  • Travel & lodging$410%
  • Food & beverage$2701%

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics9$8,860
Astrazeneca UK Limited6$8,056
HRA Pharma RARE Diseases2$5,400
AstraZeneca2$4,296
Vertex1$877
Modernatx, Inc.1$450

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,939 in reported general payments places this provider in the 80th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$8,113
Medicare patients
52
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LysodrenMitotane38$106,047
Eplerenone23$3,815
Hydrocortisone69$3,335
Fludrocortisone Acetate57$1,003
Levothyroxine Sodium35$363
Spironolactone22$150
Alendronate Sodium13$96
Amlodipine Besylate16$66

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →